SCYNEXIS, Inc. to Participate in the 2017 BIO International Convention
June 13 2017 - 9:05AM
SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering
innovative anti-infective therapies for difficult-to-treat and
often life-threatening infections, today announced that Marco
Taglietti, M.D., President and Chief Executive Officer, will
participate in a panel at the 2017 BIO International Conference at
the San Diego Convention Center on Tuesday, June 20, 2017, at 4:15
p.m. PT. The panel, “Antifungus Among Us: Recognizing Vulnerability
and Opportunity with the Next-Generation of Antifungals,” will
focus on the growing global health epidemic and highlight the
urgent needs and opportunities in the antifungal space.
About SCYNEXISSCYNEXIS, Inc. is a biotechnology
company committed to positively impacting the lives of
patients suffering from difficult-to-treat and often
life-threatening infections by delivering innovative anti-infective
therapies. The SCYNEXIS team has extensive experience in the life
sciences industry, discovering and developing more than 30
innovative medicines over a broad range of therapeutic areas. The
Company's lead product candidate, SCY-078, is the first
representative of a novel intravenous and oral triterpenoid
antifungal family and is in Phase 2 clinical development for the
treatment of several fungal infections, including serious and
life-threatening invasive fungal infections. For more
information, visit www.scynexis.com.
CONTACT:
Media Relations
Cammy Duong
MacDougall Biomedical Communications
Tel: 781-591-3443
cduong@macbiocom.com
Investor Relations
Susan Kim
Argot Partners
Tel: 212-203-4433
susan@argotpartners.com
Scynexis (NASDAQ:SCYX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Scynexis (NASDAQ:SCYX)
Historical Stock Chart
From Sep 2023 to Sep 2024